Suspension of trading
Cerevel Therapeutics Holdings, Inc. Stock
Stocks
CERE
US15678U1280
Biotechnology & Medical Research
|
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 44.96 USD | +0.74% |
|
-.--% | - |
| Market Cap | 8.19B 7.06B 6.5B 6.1B 11.46B 774B 11.58B 76.81B 29.93B 379B 30.74B 30.09B 1,314B | P/E Ratio 2022 |
-13.6x | P/E Ratio 2023 | -15.9x |
|---|---|---|---|---|---|
| Enterprise Value | 7.5B 6.46B 5.95B 5.59B 10.49B 709B 10.6B 70.29B 27.38B 347B 28.13B 27.53B 1,203B | EV / Sales 2022 |
-
| EV / Sales 2023 | - |
| Free-Float |
93.64% | Yield 2022 * |
-
| Yield 2023 | - |
| 1 day | +0.74% |
| 3 years | 19.59 |  | 44.99 |
| 5 years | 12.01 | | 46.16 |
| 10 years | 9 | | 46.16 |
| Manager | Title | Age | Since |
|---|---|---|---|
Scott Reents
PSD | President | 59 | 01/08/2024 |
John Renger
CTO | Chief Tech/Sci/R&D Officer | 57 | 01/05/2019 |
Matthew Calistri
IRC | Investor Relations Contact | - | - |
| Director | Title | Age | Since |
|---|---|---|---|
Deborah Baron
BRD | Director/Board Member | 57 | 20/01/2021 |
Scott Reents
BRD | Director/Board Member | 59 | 01/08/2024 |
| Date | Insider | Type | Main position | Quantity | % Market Cap. | |
|---|---|---|---|---|---|---|
| 01/08/24 | Issuer sale | Director | 93,932 | 0.0516% | ||
| 01/08/24 | Issuer sale | Head of Human Resources | 800,774 | 0.4395% | ||
| 01/08/24 | Issuer sale | Director | 151,795 | 0.0833% |
| Change | 5-day change | 1-year change | 3-year change | Capi.($) | ||
|---|---|---|---|---|---|---|
 | +0.74% | -.--% | -.--% | +32.20% | 8.19B | |
| +0.74% | -0.05% | +61.29% | +111.77% | 54.54B | |
| -1.22% | +5.01% | +43.38% | +36.69% | 43.86B | |
| -1.43% | +3.47% | -15.83% | -20.48% | 22.63B | |
| -1.99% | -3.55% | -5.97% | +377.60% | 20.7B | |
| -0.53% | +0.54% | +16.19% | -36.06% | 15.84B | |
| +1.83% | -1.59% | +9.82% | -40.10% | 14.83B | |
| -1.70% | -1.68% | +24.79% | +172.92% | 13.1B | |
| -5.17% | +0.50% | +21.80% | - | 12.66B | |
| +0.29% | +5.10% | +75.82% | +105.33% | 11.56B | |
| Average | -0.83% | +1.09% | +23.13% | +82.21% | 21.79B | |
| Weighted average by Cap. | -0.63% | +0.71% | +30.48% | +85.94% |
| 2022 | 2023 | |
|---|---|---|
| Net sales | - | - |
| Net income | -352M -303M -279M -262M -492M -33.23B -497M -3.3B -1.28B -16.27B -1.32B -1.29B -56.4B | -433M -373M -343M -323M -606M -40.92B -612M -4.06B -1.58B -20.04B -1.62B -1.59B -69.45B |
| Net Debt | -523M -451M -415M -390M -732M -49.47B -740M -4.91B -1.91B -24.23B -1.96B -1.92B -83.95B | -695M -599M -552M -518M -973M -65.75B -983M -6.52B -2.54B -32.2B -2.61B -2.55B -112B |
Employees
355
- Stock Market
- Stocks
- CERE Stock
Select your edition
All financial news and data tailored to specific country editions
